| Prefrontal cortex | 40-60% reduction in synaptic density |
| Motor cortex | 30-50% reduction correlating with cortical signs |
| Basal ganglia | Variable loss depending on regional involvement |
| Hippocampal involvement | Variable depending on comorbid AD pathology |
| Synaptophysin | Decreased in 70-80% of CBS cases |
| Synapsin I | Reduced in cortical regions |
| PSD-95 | Loss of postsynaptic density |
| SV2A | Reduced synaptic vesicle protein |
| Altered neurotransmission | Glutamate, GABA, acetylcholine |
| Mitochondrial dysfunction | Energy failure at synapses |
| Axonal transport disruption | Reduced synaptic proteins |
| AMPA receptor loss | Excitotoxicity vulnerability |
| Databases | OMIMOrphanetClinicalTrialsPubMed |
No AI portrait yet
No comments yet. Be the first to comment!